SUPN
Supernus Pharmaceuticals Stock Analysis
AI Rating
- Quality6/10
- Growth↓ 2/10
- Value↓ 1/10
SUPN Growth
- Revenue Y/Y↑ 8.63%
- EPS Y/Y↓ -150.75%
- FCF Y/Y↓ -73.14%
SUPN Profitability
- Gross margin ↑ 89.60%
- EPS margin↓ -5.40%
- ROIC 5Y↓ 10.77%
SUPN Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 0.0
- Interest coverage↑ 999.0
Supernus Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.